Xian Li

20020114781, Aug 22, 2002

Sep 14, 2001

09/953323

Terry Strom - Brookline MA, US
Xian Li - Newton MA, US

A61K039/395
A61K038/20

424/085200, 424/145100

The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo), reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).

20040185048, Sep 23, 2004

Dec 30, 2003

10/749699

Terry Strom - Brookline MA, US
Xian Li - Newton MA, US

Beth Israel Deaconess Medical Center, Inc., a Massachusetts corporation

A61K039/395
A61K038/17

424/145100, 514/012000

The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo), reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).

20190086486, Mar 21, 2019

Mar 9, 2018

15/917198

- Cambridge MA, US
Jian Lu - Medford MA, US
Yaqing Zhang - Cambridge MA, US
Benjamin K. Ofori-Okai - Cambridge MA, US
Keith A. Nelson - Newton MA, US
Xian Li - Cambridge MA, US

G01R 33/26
G01R 33/60
G01N 24/10
G01R 33/32

A nonlinear terahertz (THz) spectroscopy technique uses a sample illuminated by two THz pulses separately. The illumination generates two signals Band B, corresponding to the first and second THz pulse, respectively, after interaction with the sample. The interaction includes excitation of at least one ESR transition in the sample. The sample is also illuminated by the two THz pulses together, with an inter-pulse delay τ, generating a third signal B. A nonlinear signal BNL is then derived via B=B−B−B. This nonlinear signal Bcan be then processed (e.g., Fourier transform) to study the properties of the sample.

20170336482, Nov 23, 2017

May 19, 2017

15/600029

Harold Young HWANG - Cambridge MA, US
Jian Lu - Medford MA, US
Yaqing Zhang - Cambridge MA, US
Benjamin K. Ofori-Okai - Cambridge MA, US
Keith A. Nelson - Newton MA, US
Xian Li - Cambridge MA, US

G01R 33/26
G01R 33/60

A nonlinear terahertz (THz) spectroscopy technique uses a sample illuminated by two THz pulses separately. The illumination generates two signals Band B, corresponding to the first and second THz pulse, respectively, after interaction with the sample. The interaction includes excitation of at least one ESR transition in the sample. The sample is also illuminated by the two THz pulses together, with an inter-pulse delay τ, generating a third signal B. A nonlinear signal BNL is then derived via B=B−B−B. This nonlinear signal Bcan be then processed (e.g., Fourier transform) to study the properties of the sample.